WILEX

About:

WILEX is a biopharmaceutical company developing drugs and diagnostic agents to detect and treat malignant tumors and cancers.

Website: http://www.wilex.de

Top Investors: Earlybird Venture Capital, Apax Partners, Yorkville Advisors, TVM Capital, Techno Venture Management

Description:

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.